Panel Discussion: Reaching, Enrolling, and Retaining Participants in Rare Disease Gene Therapy Trials

Time: 2:00 pm
day: Clinical - PM

Details:

• Multi-stakeholder discussion of friction points in the development lifecycle and how to overcome them: what have we tried, what has been successful and under what circumstances
• Dissection of real-world examples over time and across different patient communities
• Analysis of recent trends and impacts of continuing advances

Speakers:

Amy Raymond Amy has been a drug discovery and development professional for 25+ years, including progressive roles in clinical operations and clinical strategy. Her clinical development experience Read more

Mitra Tavakkoli Executive physician scientist with extensive rare disease gene therapy drug development experience

Pat Furlong With three decades of expertise in translational medicine Pat Furlong, president and CEO of PPMD, has led ground-breaking research and cultivated meaningful patient engagement strategies, Read more

Tessa Field

Doreen Morgan Doreen V. Morgan, Pharm.D., M.S., RPh. has extensive career experience in drug development and global regulatory strategy expertise in small and large molecules, cell and Read more